Treatment approaches currently applied to HER2-positive (HER2+) cancers include the small molecule inhibitor Lapatinib, the inhibitory antibody Trastuzumab, and the antibody-drug conjugate Trastuzumab Emtansine (T-DM1)7–9. This evidence concerns the gene ERBB2 and cancer.